Search

Your search keyword '"Alpha blockers"' showing total 3 results
Start Over Descriptor "Alpha blockers" Journal central european journal of urology
3 results on '"Alpha blockers"'

1. The industrial revolution for the management of benign prostate obstruction: worldwide publication trends for surgical and medical therapies over the past two decades

Author

Bhavan Prasad Rai, Patrick Jones, Jeremy Nettleton, Laurian Dragos, Marcus J. Drake, Amelia Pietropaolo, Domenico Veneziano, Bhaskar K. Somani, and Robert Geraghty

Subjects
Laser surgery, medicine.medical_specialty, medicine.medical_treatment, 030232 urology & nephrology, Urology, 5-alpha reductase inhibitor, alpha blockers, Resection, 03 medical and health sciences, 0302 clinical medicine, systematic review, Prostate, Lower urinary tract symptoms, Medicine, lower urinary tract symptoms, minimally invasive surgery, Review Paper, benign prostatic hyperplasia, business.industry, General Medicine, medicine.disease, medicine.anatomical_structure, Greenlight laser, 030220 oncology & carcinogenesis, benign prostatic obstruction, Alpha blocker, business, Benign prostate, Systematic search
Abstract

Introduction Research for management of benign prostate obstruction (BPO) for adult males remains a cornerstone of urology research. This landscape has witnessed the rise and fall of multiple therapies, both surgical and medical. Our aim was to formally evaluate the publication trends for these interventions over the past 20 years. Material and methods A systematic search was performed in a Cochrane style. Data was analysed using the independent t-test and Pearson's correlation coefficient (SPSS version 24). To observe changes in trends more effectively, data was sub-divided into two time periods: 1997 to 2006 and 2007 to 2016. Results Over the past 20 years, 4236 papers have been published concerning for BPO (surgical, n = 2177 and medical, n = 2059). For surgical treatments, these included articles on monopolar transurethral resection of prostate (TURP) (n = 340), bipolar TURP (n = 260), HoLEP (n = 293) and Greenlight laser (n = 395). For medical therapies, these included alpha blockers (848), 5-alpha reductase inhibitors (n = 618) and PDE5I (n = 91). Between the two time periods the change was +18.8% (p = 0.108) for monopolar TURP, +497.1% (

Published
2019
Full Text
View/download PDF

2. Effectiveness of 'on demand' silodosin in the treatment of premature ejaculation in patients dissatisfied with dapoxetine: a randomized control study

Author

Gajanan S. Bhat and Anuradha Shastry

Subjects
medicine.medical_specialty, Ejaculation, 030232 urology & nephrology, Placebo, alpha blockers, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, selective serotonin reuptake inhibitors, male sexual dysfunction, Premature ejaculation, medicine, Adverse effect, Gynecology, Original Paper, business.industry, General Medicine, Silodosin, Dapoxetine, premature ejaculation, 030220 oncology & carcinogenesis, Anesthesia, Clinical Global Impression, medicine.symptom, business, medicine.drug
Abstract

INTRODUCTION Premature ejaculation is a common sexual disorder, which is usually underreported. Multiple treatment methodologies are in use due to the absence of an effective, universally acceptable treatment modality. The most common drug used is dapoxetine, which has adverse effects limiting its long-term use. Hence, we decided to evaluate the effectiveness of 'on demand' silidosin 4 mg in patients with premature ejaculation, who were dissatisfied with dapoxetine 30 mg. MATERIAL AND METHODS The study included 64 patients who reported premature ejaculation who were unhappy with the treatment with 'on demand' dapoxetine 30 mg, either due to its adverse effects or because of its overall inefficacy. They were divided into two groups of 33 and 31 respectively by simple randomization, with Group A treated with 'on demand' silodosin 4 mg three hours prior to intercourse, whereas Group B was treated with placebo. Pre- and post-treatment intravaginal ejaculatory latency time (IELT), premature ejaculation profile (PEP) and clinical global impression of change (CGIC) for premature ejaculation were evaluated. RESULTS Patients in Group A (silodosin 4 mg) reported statistically significant improvement (p

Published
2016

3. Effectiveness of 'on demand' silodosin in the treatment of premature ejaculation in patients dissatisfied with dapoxetine: a randomized control study.

Author

Bhat GS and Shastry A

Abstract

Introduction: Premature ejaculation is a common sexual disorder, which is usually underreported. Multiple treatment methodologies are in use due to the absence of an effective, universally acceptable treatment modality. The most common drug used is dapoxetine, which has adverse effects limiting its long-term use. Hence, we decided to evaluate the effectiveness of 'on demand' silidosin 4 mg in patients with premature ejaculation, who were dissatisfied with dapoxetine 30 mg., Material and Methods: The study included 64 patients who reported premature ejaculation who were unhappy with the treatment with 'on demand' dapoxetine 30 mg, either due to its adverse effects or because of its overall inefficacy. They were divided into two groups of 33 and 31 respectively by simple randomization, with Group A treated with 'on demand' silodosin 4 mg three hours prior to intercourse, whereas Group B was treated with placebo. Pre- and post-treatment intravaginal ejaculatory latency time (IELT), premature ejaculation profile (PEP) and clinical global impression of change (CGIC) for premature ejaculation were evaluated., Results: Patients in Group A (silodosin 4 mg) reported statistically significant improvement (p <0.005) in intravaginal ejaculatory latency time (IELT), premature ejaculation profile (PEP) and clinical global impression of change (CGIC) for premature ejaculation, with four patients reporting uncomfortably-delayed ejaculation., Conclusions: 'On demand' silodosin 4 mg is an effective treatment option with very few adverse events in those patients suffering from premature ejaculation, who are dissatisfied with dapoxetine 30 mg due to its adverse effects or inefficacy., Competing Interests: The authors declare no conflicts of interest.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results